Skip to main
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is a clinical-stage biotechnology company with a promising drug candidate in its pipeline. Despite the company's sole focus on research and development, its lead drug ANB033 has shown early effectiveness in clinical trials for multiple diseases and has potential for use in treating other inflammatory diseases. While the company faces risks and is also working on two other potential treatments, ANB033 could provide a comprehensive treatment option for patients with celiac disease and eosinophilic esophagitis who have not responded to current options.

Bears say

First Tracks is currently operating in a single reportable segment, focusing solely on research and development activities for immunology therapeutics. While the company's pipeline appears promising, with three differentiated assets in hand and potential across a range of inflammatory diseases, their financials may be impacted by the high research and development costs associated with clinical trials and the need for a strategic partner or non-dilutive capital to advance rosnilimab. Additionally, the late-stage clinical data for their lead candidate, rosnilimab, in rheumatoid arthritis, did not show statistically significant benefits and there are uncertainties surrounding the mechanistic landscape of their other candidates in development. Therefore, the company may face challenges in generating profitable revenue in the near future, making its stock less attractive for investment.

TRAX has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 7 analysts, TRAX has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.